Related Experiment Videos
[Ganglionar metastization on radical prostatectomy].
Mário Reis1, Francisco Pina, Macedo Dias
1Serviços de Urologia e Anatomia Patológica, Hospital de S. João, Serviço de Epidemiologia, Faculdade de Medicina do Porto.
Acta Medica Portuguesa
|January 8, 2005
Summary
Pelvic lymph node disease after prostatectomy is decreasing. Adjuvant radiotherapy and hormone treatment show similar survival rates to other methods for positive lymph nodes, but further study is needed.
Area of Science:
- Urology
- Oncology
- Surgical Pathology
Context:
- Radical prostatectomy is a primary treatment for localized prostate cancer.
- Pelvic lymph node metastasis is a significant prognostic factor.
- The role and extent of pelvic lymphadenectomy remain subjects of debate.
Purpose:
- To retrospectively analyze outcomes in patients with positive pelvic lymph nodes after radical prostatectomy.
- To evaluate the efficacy of a specific treatment protocol involving adjuvant radiotherapy and hormone therapy.
- To discuss the current indications and controversies surrounding pelvic lymphadenectomy.
Summary:
- A retrospective analysis of 19 patients with positive pelvic lymph nodes (4.2% of 450) following radical prostatectomy was conducted.
- The 5-year survival probability was 60.9%, with a biochemical recurrence-free survival of 37.5%.
- A treatment protocol combining adjuvant radiotherapy and hormone therapy demonstrated survival rates comparable to other studies.
Impact:
- Suggests a declining incidence of lymph node involvement in prostate cancer patients undergoing surgery.
- Highlights the need for individualized treatment strategies rather than routine lymphadenectomy.
- Supports the use of combined adjuvant radiotherapy and hormone therapy for extensive disease pending further randomized trials.